
NeurologyLive® Friday 5 — September 4, 2026
Key Takeaways
- Updated multiple sclerosis criteria reinforce earlier diagnosis and support a treatment strategy favoring early high-efficacy therapy, while progressive MS continues to represent a major unmet clinical need.
- Movement disorders priorities include transitioning Parkinson disease toward a biologic definition, integrating newly approved therapies, and reducing delays by referring suspected cases earlier to specialists.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 4, 2026.
Welcome to NeurologyLive®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
Click the read more or watch now buttons for more details and information about each highlight.
1: Advancing Early Diagnosis and Treatment Strategies in Multiple Sclerosis
In a recent Q&A interview, Hannah Kopinsky, MD, an MS specialist at Northwestern Medicine, discussed recent updates to multiple sclerosis diagnostic criteria, the shift toward early high-efficacy treatment, and the unmet needs that remain in progressive MS.
2: Charting the Next Wave of Advancements in Movement Disorders Care
In a recent Q&A interview, Lucy Morse, MD, a movement disorders specialist at Northwestern Medicine, discussed the push toward a biological definition for Parkinson disease, newly approved therapies, and why she believes referrals shouldn't wait.
3: Overviewing First-Ever Platform Trial for Progressive Supranuclear Palsy: Julio Rojas, MD, PhD
In a recent video interview, Julio Rojas, MD, PhD, a neurologist at the UCSF Edward and Pearl Fein Memory and Aging Center, discusses how the first platform trial in progressive supranuclear palsy could accelerate the evaluation of potential disease-modifying therapies. [WATCH TIME: 4 minutes]
4: NeuroVoices: Lorie Richards, PhD, OTR/L, on New 2026 AHA/ASA Stroke Rehabilitation Guideline
In our latest NeuroVoices, Lorie Richards, PhD, OTR/L, the chair of the 2026 AHA/ASA Guideline for Adult Stroke Rehabilitation and Recovery, discussed the major themes, clinical takeaways, and unanswered questions from the first update to the guideline in a decade.
5: Q&A Part 1: CTE Prevalence, Brain Donation Findings in Former NFL Players: Thayne Munce, PhD
In a recent Q&A interview, Thayne Munce, PhD, a member of the leadership council at the Wu Tsai Human Performance Alliance and site director of the Alliance at the University of Kentucky, discussed a recent study's approach to examining CTE in former NFL players.
Which conversation stood out most to you in this week’s NeurologyLive Friday Five?
Don’t have time to read or watch a full video interview?











